Vivo Capital’s AN2 Therapeutics ANTX Stock Holding History

Vivo Capital’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.3M	Hold	3,153,640	–	–	1.39%	26
2026 Q1	$10.8M	Buy	+3,153,640	New	+$6.51M	0.9%	29

Other funds holding ANTX

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vivo Capital's ANTX Position: Q2 2026 in Review

Vivo Capital held its AN2 Therapeutics (ANTX) position steady in Q2 2026 at 3,153,640 shares worth $15.3M. The position accounts for 1.39% of the portfolio, ranked #26.

Vivo Capital first reported a position in ANTX in Q1 2026 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

Vivo Capital held 3,153,640 shares of AN2 Therapeutics worth $15.3M as of Q2 2026.
Vivo Capital left its AN2 Therapeutics share count unchanged in Q2 2026.
AN2 Therapeutics made up 1.39% of Vivo Capital's portfolio in Q2 2026, its #26 holding.
Vivo Capital first reported a position in AN2 Therapeutics in Q1 2026 and has held it in 2 quarters since.
59 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.